Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:LIVNNYSE:STVNNASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$100.32-2.0%$93.91$77.10▼$163.71$5.73B0.8736,575 shs1.88 million shsLIVNLivaNova$45.51+0.8%$41.63$32.48▼$57.35$2.48B0.9643,707 shs910,276 shsSTVNStevanato Group€23.38-1.6%€22.77€16.56▼€25.75$7.08B0.53291,683 shs377,700 shsTMDXTransMedics Group$123.56-0.4%$114.23$55.00▼$177.37$4.18B2.11.37 million shs1.29 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos0.00%+2.70%+4.26%-6.86%-11.23%LIVNLivaNova0.00%-0.55%+8.67%+12.73%-18.96%STVNStevanato Group0.00%-0.09%+5.13%+4.66%+31.42%TMDXTransMedics Group0.00%-13.52%-0.56%+72.88%-11.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.4931 of 5 stars4.42.00.04.42.22.50.6LIVNLivaNova3.402 of 5 stars3.54.00.00.03.01.71.3STVNStevanato GroupN/AN/AN/AN/AN/AN/AN/AN/ATMDXTransMedics Group1.3105 of 5 stars1.42.00.00.01.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6734.23% UpsideLIVNLivaNova 3.00Buy$59.2930.27% UpsideSTVNStevanato Group 2.86Moderate BuyN/AN/ATMDXTransMedics Group 2.80Moderate Buy$127.333.05% UpsideCurrent Analyst Ratings BreakdownLatest LIVN, STVN, GKOS, and TMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.006/17/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/20/2025LIVNLivaNovaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$60.005/13/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.005/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.005/8/2025LIVNLivaNovaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $55.005/8/2025LIVNLivaNovaRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $61.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M14.95N/AN/A$13.91 per share7.21LIVNLivaNova$1.25B1.98$4.24 per share10.73$24.31 per share1.87STVNStevanato Group$1.19B5.93€0.76 per share30.85€5.02 per share4.66TMDXTransMedics Group$441.54M9.46$1.65 per share75.09$6.81 per share18.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)LIVNLivaNova$63.23M-$4.09N/A14.49N/A-17.41%13.67%6.68%7/30/2025 (Estimated)STVNStevanato Group$127.45M€0.5145.8440.312.2211.14%10.00%6.03%N/ATMDXTransMedics Group$35.46M$1.3690.8586.41N/A10.03%21.88%6.15%7/30/2025 (Estimated)Latest LIVN, STVN, GKOS, and TMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest LIVN, STVN, GKOS, and TMDX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.096.495.62LIVNLivaNova0.531.581.37STVNStevanato Group0.221.831.26TMDXTransMedics Group1.929.108.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%LIVNLivaNova97.64%STVNStevanato GroupN/ATMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos6.40%LIVNLivaNova0.29%STVNStevanato GroupN/ATMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million53.48 millionOptionableLIVNLivaNova2,90054.53 million54.37 millionOptionableSTVNStevanato Group5,521302.84 millionN/AOptionableTMDXTransMedics Group21033.82 million31.46 millionOptionableLIVN, STVN, GKOS, and TMDX HeadlinesRecent News About These CompaniesTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cornerstone Wealth Management LLCJune 21 at 4:05 AM | marketbeat.comBrokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $125.11June 20 at 1:53 AM | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by SG Americas Securities LLCJune 19, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00 at OppenheimerJune 19, 2025 | americanbankingnews.comBoasting A 18% Return On Equity, Is TransMedics Group, Inc. (NASDAQ:TMDX) A Top Quality Stock?June 18, 2025 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 4.9% - Should You Sell?June 18, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00June 17, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to ConnectJune 17, 2025 | accessnewswire.comTransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLCJune 17, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 17, 2025 | marketbeat.comHandelsbanken Fonder AB Sells 72,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)June 16, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach OutJune 15, 2025 | accessnewswire.comPrice Over Earnings Overview: TransMedics GroupJune 13, 2025 | benzinga.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities InvestigationJune 12, 2025 | accessnewswire.comMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayJune 12, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,902.80 in StockJune 11, 2025 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 686 Shares of StockJune 10, 2025 | marketbeat.comKuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law FirmJune 10, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the InvestigationJune 10, 2025 | accessnewswire.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryJune 9, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayLIVN, STVN, GKOS, and TMDX Company DescriptionsGlaukos NYSE:GKOS$100.32 -2.02 (-1.97%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$100.14 -0.18 (-0.18%) As of 06/20/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.LivaNova NASDAQ:LIVN$45.51 +0.34 (+0.75%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$45.52 +0.01 (+0.01%) As of 06/20/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.Stevanato Group NYSE:STVN€23.38 -0.37 (-1.56%) As of 06/20/2025 03:58 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.TransMedics Group NASDAQ:TMDX$123.56 -0.44 (-0.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$123.00 -0.56 (-0.45%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
